PROS1 and COVID-19: A placebo-controlled phase 1–2 trial involving 131 healthy adults compared the reactogenicity and safety of anti-S protein IgG titers generated from the administration of NVX-CoV2373 to convalescent serum from symptomatic COVID-19 patients.